147 related articles for article (PubMed ID: 31911828)
1. Toxicity management of regorafenib in patients with gastro-intestinal stromal tumour (GIST) in a tertiary cancer centre.
Chamberlain F; Farag S; Williams-Sharkey C; Collingwood C; Chen L; Mansukhani S; Engelmann B; Al-Muderis O; Chauhan D; Thway K; Fisher C; Jones RL; Gennatas S; Benson C
Clin Sarcoma Res; 2020; 10():1. PubMed ID: 31911828
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.
Ben-Ami E; Barysauskas CM; von Mehren M; Heinrich MC; Corless CL; Butrynski JE; Morgan JA; Wagner AJ; Choy E; Yap JT; Van den Abbeele AD; Solomon SM; Fletcher JA; Demetri GD; George S
Ann Oncol; 2016 Sep; 27(9):1794-9. PubMed ID: 27371698
[TBL] [Abstract][Full Text] [Related]
3. Real-world experience of safety and effectiveness of regorafenib for treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumors, and hepatocellular carcinoma: a post-marketing surveillance study in Korea.
Beom SH; Bae KB; Zang DY; Bae J; Hwang IG; Kang HJ; Woo IS; Shim BY; Bae BN; Cheon J; Oh SB; Ahn JB
J Cancer; 2022; 13(13):3396-3403. PubMed ID: 36313033
[No Abstract] [Full Text] [Related]
4. Case Report: Should Regorafenib be prescribed as a continuous schedule in gastrointestinal stromal tumors? Three case reports on Regorafenib personalized schedule.
Grimaudo MS; Laffi A; Gennaro N; Fazio R; D'Orazio F; Samà L; Siracusano LV; Sicoli F; Renne SL; Santoro A; Bertuzzi AF
Front Oncol; 2023; 13():1190123. PubMed ID: 37324004
[TBL] [Abstract][Full Text] [Related]
5. Real-life treatment of metastatic colorectal cancer with regorafenib: a single-centre review.
Gotfrit J; Vickers M; Sud S; Asmis T; Cripps C; Goel R; Hsu T; Jonker D; Goodwin R
Curr Oncol; 2017 Aug; 24(4):234-239. PubMed ID: 28874891
[TBL] [Abstract][Full Text] [Related]
6. Hepatic toxicity during regorafenib treatment in patients with metastatic gastrointestinal stromal tumors.
Ivanyi P; Eggers H; Hornig M; Kasper B; Heissner K; Kopp HG; Kirstein M; Ganser A; Grünwald V
Mol Clin Oncol; 2020 Dec; 13(6):72. PubMed ID: 33005406
[TBL] [Abstract][Full Text] [Related]
7. Standard versus personalized schedule of regorafenib in metastatic gastrointestinal stromal tumors: a retrospective, multicenter, real-world study.
Nannini M; Rizzo A; Nigro MC; Vincenzi B; Mazzocca A; Grignani G; Merlini A; D'Ambrosio L; Tolomeo F; Badalamenti G; Incorvaia L; Bonasera A; Fumagalli E; Miliziano D; Ligorio F; Brunello A; Chiusole B; Gasperoni S; Novelli M; Pantaleo MA
ESMO Open; 2021 Aug; 6(4):100222. PubMed ID: 34352702
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
Demetri GD; Reichardt P; Kang YK; Blay JY; Rutkowski P; Gelderblom H; Hohenberger P; Leahy M; von Mehren M; Joensuu H; Badalamenti G; Blackstein M; Le Cesne A; Schöffski P; Maki RG; Bauer S; Nguyen BB; Xu J; Nishida T; Chung J; Kappeler C; Kuss I; Laurent D; Casali PG;
Lancet; 2013 Jan; 381(9863):295-302. PubMed ID: 23177515
[TBL] [Abstract][Full Text] [Related]
9. Treatment patterns, efficacy and toxicity of regorafenib in gastrointestinal stromal tumour patients.
Schvartsman G; Wagner MJ; Amini B; Zobniw CM; Trinh VA; Barbo AG; Lin HY; Wang WL; Conley AP; Ravi V; Araujo DM; Zarzour MA; Benjamin RS; Patel S; Somaiah N
Sci Rep; 2017 Aug; 7(1):9519. PubMed ID: 28842575
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study.
Dane F; Ozgurdal K; Yalçın Ş; Benekli M; Aykan NF; Yücel İ; Özkan M; Evrensel T; Sevinç A; Coskun HŞ; Sanli UA; Kara IO; Yumuk PF
BMJ Open; 2020 Mar; 10(3):e027665. PubMed ID: 32220908
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of the oral multikinase inhibitor regorafenib and its association with real-world treatment outcomes.
Fukudo M; Asai K; Tani C; Miyamoto M; Ando K; Ueno N
Invest New Drugs; 2021 Oct; 39(5):1422-1431. PubMed ID: 33830408
[TBL] [Abstract][Full Text] [Related]
12. Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients.
Novakova-Jiresova A; Kopeckova K; Boublikova L; Chloupkova R; Melichar B; Petruzelka L; Finek J; Fiala O; Grell P; Batko S; Linke Z; Kiss I; Prausova J; Buchler T
Cancer Manag Res; 2020; 12():5365-5372. PubMed ID: 32753954
[TBL] [Abstract][Full Text] [Related]
13. Regorafenib treatment for advanced, refractory gastrointestinal stromal tumor: a report of the UK managed access program.
Kollàr A; Maruzzo M; Messiou C; Cartwright E; Miah A; Martin-Liberal J; Thway K; McGrath E; Dunlop A; Khabra K; Seddon B; Dileo P; Linch M; Judson I; Benson C
Clin Sarcoma Res; 2014; 4():17. PubMed ID: 25905001
[TBL] [Abstract][Full Text] [Related]
14. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.
Eng C; Kim TW; Bendell J; Argilés G; Tebbutt NC; Di Bartolomeo M; Falcone A; Fakih M; Kozloff M; Segal NH; Sobrero A; Yan Y; Chang I; Uyei A; Roberts L; Ciardiello F;
Lancet Oncol; 2019 Jun; 20(6):849-861. PubMed ID: 31003911
[TBL] [Abstract][Full Text] [Related]
15. Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study.
Ducreux M; Petersen LN; Öhler L; Bergamo F; Metges JP; de Groot JW; Wang JY; García Paredes B; Dochy E; Fiala-Buskies S; Cervantes A; O'Connor JM; Falcone A;
Eur J Cancer; 2019 Dec; 123():146-154. PubMed ID: 31698328
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Regorafenib in Metastatic Colorectal Cancer: A Multi-institutional Retrospective Study.
Aljubran A; Elshenawy MA; Kandil M; Zahir MN; Shaheen A; Gad A; Alshaer O; Alzahrani A; Eldali A; Bazarbashi S
Clin Med Insights Oncol; 2019; 13():1179554918825447. PubMed ID: 30728734
[TBL] [Abstract][Full Text] [Related]
17. Cytoreductive Surgery may be beneficial for highly selected patients with Metastatic Gastrointestinal Stromal Tumors receiving Regorafenib facing Local Progression: A Case Controlled Study.
Yeh CN; Hu CH; Wang SY; Wu CE; Chen JS; Tsai CY; Hsu JT; Yeh TS
J Cancer; 2021; 12(11):3335-3343. PubMed ID: 33976743
[No Abstract] [Full Text] [Related]
18. A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib.
Penel N; Mir O; Wallet J; Ray-Coquard I; Le Cesne A; Italiano A; Salas S; Delcambre C; Bompas E; Bertucci F; Saada-Bouzid E; Chaigneau L; Chevreau C; Brodowicz T; Decoupigny E; Vanseymortier M; Laroche L; Taieb S; Le Deley MC; Blay JY
Eur J Cancer; 2020 Feb; 126():45-55. PubMed ID: 31918233
[TBL] [Abstract][Full Text] [Related]
19. A phase II study on the efficacy of regorafenib in treating patients with c-KIT-mutated metastatic malignant melanoma that progressed after previous treatment (KCSG-UN-14-13).
Kim KH; Jung M; Lee HJ; Lee SJ; Kim M; Ahn MS; Choi MY; Lee NR; Shin SJ;
Eur J Cancer; 2023 Nov; 193():113312. PubMed ID: 37741071
[TBL] [Abstract][Full Text] [Related]
20. Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial.
Lombardi G; De Salvo GL; Brandes AA; Eoli M; Rudà R; Faedi M; Lolli I; Pace A; Daniele B; Pasqualetti F; Rizzato S; Bellu L; Pambuku A; Farina M; Magni G; Indraccolo S; Gardiman MP; Soffietti R; Zagonel V
Lancet Oncol; 2019 Jan; 20(1):110-119. PubMed ID: 30522967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
